Protein Expression in Samples From Young Patients With Rhabdomyosarcoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01426945|
Recruitment Status : Completed
First Posted : September 1, 2011
Last Update Posted : May 18, 2016
RATIONALE: Studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial studies protein expression in samples from young patients with rhabdomyosarcoma.
|Condition or disease||Intervention/treatment|
|Sarcoma||Genetic: protein expression analysis Other: immunohistochemistry staining method Other: laboratory biomarker analysis|
- To measure the protein expression of candidate proteins in human rhabdomyosarcoma (RMS) tumor samples.
OUTLINE: Archived tumor tissue samples are analyzed for protein expression (i.e., Notch1, Hey1, FGFR4, and Sp1) by IHC techniques and standard commercially available antibodies. Candidate proteins are then correlated with each patient age, gender, rhabdomyosarcoma (RMS) tumor stage, and RMS tumor subtype.
|Study Type :||Observational|
|Estimated Enrollment :||77 participants|
|Official Title:||Evaluating Candidate Protein Expression in Human Rhabdomyosarcoma (RMS)|
|Study Start Date :||November 2011|
|Actual Primary Completion Date :||May 2016|
- RMS protein expression profile
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01426945
|Principal Investigator:||Corinne M. Linardic, MD, PhD||Duke Cancer Institute|